新開源(300109.SZ)簽署解決資金佔用協議
格隆匯11月1日丨新開源(300109.SZ)公佈,2019年11月1日,公司召開了第四屆董事會第四次會議審議通過了《關於簽署
<關於解決北京晨旭達投資有限公司資金佔用協議>
的議案》、《關於簽署
<關於解決北京國澤資本管理有限公司資金佔用協議>
的議案》。
關於解決北京國澤資本管理有限公司資金佔用協議>
關於解決北京晨旭達投資有限公司資金佔用協議>
2018年9月30日至2019年2月28日,公司全資子公司北京新開源精準醫療科技有限公司(“北京新開源”)與北京晨旭達投資有限公司(“北京晨旭達”)發生往來款人民幣共計4745.50萬元。北京晨旭達系公司5%以上股東、原董事長方華生身邊工作人員近親屬設立(持股50%)並擔任法人的公司,實際受方華生控制。
2018年12月17日,公司子公司博愛新開源生物科技有限公司(“生物科技”)與北京國澤資本管理有限公司(“國澤資本”)簽訂了《資金佔用協議》;2018年12月18日,生物科技向國澤資本支付往來款4500萬元整。國澤資本系公司5%以上股東、原董事長方華生配偶鮑婕持股並擔任法定代表人的公司,實際受方華生控制。
現為切實保障上市公司及股東的合法權益,保證公司資金安全,鑑於方華生持有公司2133.04萬股(至2020年一季度末可流通),並持有其他可變現資產,公司認為由方華生承擔連帶擔保還款責任可以最大程度降低產生壞賬的風險以保證公司及股東的合法權益。公司子公司北京新開源與北京晨旭達與方華生簽署《關於解決北京晨旭達投資有限公司資金佔用問題的協議》;公司子公司生物科技與國澤資本與方華生簽署《關於解決北京國澤資本管理有限公司資金佔用問題的協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.